Tag: Cancer: Breast
Statin Use Improves Survival in Triple-Negative Breast Cancer
Overall survival, breast cancer-specific survival improved among women with TNBC, but not those without TNBC
Five-Year Extended Hormone Therapy No Better in Breast Cancer
Findings compared with two years of extended adjuvant anastrozole in postmenopausal women with hormone-receptor-positive breast cancer
No Benefit Seen From Adjuvant Celecoxib in ERBB2-Negative Breast Cancer
Disease-free survival did not improve with two years of celecoxib versus placebo in ERBB2-negative breast cancer
Impact of Pandemic Projected for U.S. Breast Cancer Mortality
Cumulative increase of 0.52 percent expected in breast cancer deaths by 2030 due to disruptions during the first six months of the pandemic
Disparities in Breast Cancer Survival Persist for Black Women
Although nearly all metrics improved for racial-ethnic minorities, recent breast cancer-related mortality in Florida still higher in Black women
ASCO Updates Recommendations for Managing Hereditary Breast Cancer
Rapid recommendation provides updated guidance on the use of adjuvant olaparib
Ovarian Stimulation Drugs Not Tied to Higher Breast Cancer Risk
Use of clomiphene citrate or gonadotropins, alone or in combination, not associated with increased risk for breast cancer
Women’s Cancer Screenings Plummeted During Pandemic
Decline especially noticeable among women of racial and ethnic minority groups with low incomes
Breast Cancer Prognosis No Better With Five Versus Two Years of Zoledronate
No significant difference found in disease-free survival, overall survival, distant disease-free survival for five versus two years of treatment
Breast Cancer Risk Up With Inflammatory Potential of Diet
Women in highest quintile of inflammatory score of the diet had significantly increased risk, especially premenopausal women
